Tempus, a health technology company focused on personalized oncology care, will collect and analyze clinical and molecular data to support Moores Cancer Center’s research on immune checkpoint inhibitors across cancer types.
The company will also help the center incorporate genomic data into its clinical and research practices.
“Collecting and analyzing patients’ molecular, treatment and outcome data will be transformative for patients, researchers and the healthcare ecosystem,” said Eric Lefkofsky, co-founder and CEO of Tempus.
More articles on health IT:
Bloomberg: Kaspersky Lab tied to Russian government
3 Florida ACOs tap eClinicalWorks for population health management
Norwegian academic, healthcare institutions partner for blockchain research network
